Wolfgang Oster

Wolfgang Oster

UNVERIFIED PROFILE

Are you Wolfgang Oster?   Register this Author

Register author
Wolfgang Oster

Wolfgang Oster

Publications by authors named "Wolfgang Oster"

Are you Wolfgang Oster?   Register this Author

14Publications

476Reads

49Profile Views

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

Cell Cycle 2017 Oct 10;16(19):1790-1799. Epub 2017 May 10.

a Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Department of Hematology/Oncology, Fox Chase Cancer Center , Philadelphia , PA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2017.1325046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628644PMC
October 2017

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Oncotarget 2017 Oct 12;8(45):79298-79304. Epub 2017 May 12.

Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.17837DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668041PMC
October 2017

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.

Oncotarget 2017 Oct 12;8(47):81776-81793. Epub 2017 Sep 12.

Department of Hematology/Oncology, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20819DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669847PMC
October 2017

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.

Mol Cancer Ther 2017 07 19;16(7):1290-1298. Epub 2017 Apr 19.

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564301PMC
July 2017